share_log

Allarity Therapeutics | 8-K: Current report

Allarity Therapeutics | 8-K: Current report

Allarity Therapeutics | 8-K：重大事件
美股SEC公告 ·  2024/08/21 23:00

Moomoo AI 已提取核心信息

Allarity Therapeutics has completed a private placement of 35,000 shares of Series A Convertible Redeemable Preferred Stock, raising $3.15M at $90 per share. The preferred stock is convertible to common stock at $0.17 per share and holders have redemption rights within 90 days of closing. The proceeds are held in escrow pending the redemption period.The company has amended its license agreement with Eisai for Stenoparib, extending the deadline for Phase 2 Clinical Trial completion to April 1, 2028. Allarity agreed to pay Eisai a $1.25M extension payment in three installments, which has been fully paid. The trial requires achieving either 20% overall response rate or meeting other agreed endpoints.Nasdaq has approved Allarity's continued listing, contingent upon shareholder approval of a reverse stock split by September 6, 2024. The split must achieve a ratio sufficient to meet Nasdaq's minimum bid price requirement. The preferred stock holders have agreed to vote in favor of the reverse split proposal.
Allarity Therapeutics has completed a private placement of 35,000 shares of Series A Convertible Redeemable Preferred Stock, raising $3.15M at $90 per share. The preferred stock is convertible to common stock at $0.17 per share and holders have redemption rights within 90 days of closing. The proceeds are held in escrow pending the redemption period.The company has amended its license agreement with Eisai for Stenoparib, extending the deadline for Phase 2 Clinical Trial completion to April 1, 2028. Allarity agreed to pay Eisai a $1.25M extension payment in three installments, which has been fully paid. The trial requires achieving either 20% overall response rate or meeting other agreed endpoints.Nasdaq has approved Allarity's continued listing, contingent upon shareholder approval of a reverse stock split by September 6, 2024. The split must achieve a ratio sufficient to meet Nasdaq's minimum bid price requirement. The preferred stock holders have agreed to vote in favor of the reverse split proposal.
Allarity Therapeutics 完成了 35,000 股 A 系列可转换可赎回优先股的定向增发，筹集了 315万美元，股价为每股 90 美元。优先股可按每股 0.17 美元转换为普通股，持有人在完成后的 90 天内享有赎回权。所得款项在赎回期内由托管方保管。公司已修改与 Eisai 的许可协议，将 Stenoparib 的第二阶段临床试验完成期限延长至 2028 年 4 月 1 日。Allarity 同意向 Eisai 支付 125万美元的延期付款，分三期支付，目前已全部支付。该试验的要求是达到 20% 的总体反应率或符合其他约定的终点。纳斯达克已批准 Allarity 继续上市，前提是股东在 2024 年 9 月 6 日之前批准反向股票拆分。拆分必须达到足以满足纳斯达克最低买盘价格要求的比例。优先股持有人已同意投票支持反向拆分提案。
Allarity Therapeutics 完成了 35,000 股 A 系列可转换可赎回优先股的定向增发，筹集了 315万美元，股价为每股 90 美元。优先股可按每股 0.17 美元转换为普通股，持有人在完成后的 90 天内享有赎回权。所得款项在赎回期内由托管方保管。公司已修改与 Eisai 的许可协议，将 Stenoparib 的第二阶段临床试验完成期限延长至 2028 年 4 月 1 日。Allarity 同意向 Eisai 支付 125万美元的延期付款，分三期支付，目前已全部支付。该试验的要求是达到 20% 的总体反应率或符合其他约定的终点。纳斯达克已批准 Allarity 继续上市，前提是股东在 2024 年 9 月 6 日之前批准反向股票拆分。拆分必须达到足以满足纳斯达克最低买盘价格要求的比例。优先股持有人已同意投票支持反向拆分提案。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Moleculin Biotech
    MBRX
    -- 2.1800
    Allogene Therapeutics
    ALLO
    -- 2.040
    CNS Pharmaceuticals
    CNSP
    -- 0.1400
    Tenaya Therapeutics
    TNYA
    -- 1.200
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.3400
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    重磅财报来袭！2025年中国资产前景如何？
    近期，Goldman Sachs、Morgan Stanley、Appaloosa LP等多家机构唱好中国资产。 🎙️讨论： 1. Deepseek引发了中国资产的一轮上涨。你对未来市场的看法如何？ 2. 包括 $阿里巴巴 (BABA.US)$ 和 展开
    中国的资产重估引发了讨论：mooer们在买什么？